
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.4 20241031//EN" "JATS-archivearticle1-4-mathml3.dtd">
<article xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicina (Kaunas)</journal-id><journal-id journal-id-type="iso-abbrev">Medicina (Kaunas)</journal-id><journal-id journal-id-type="pmc-domain-id">3494</journal-id><journal-id journal-id-type="pmc-domain">medicina</journal-id><journal-id journal-id-type="nlm-id">9425208</journal-id><journal-id journal-id-type="publisher-id">medicina</journal-id><journal-title-group><journal-title>Medicina</journal-title></journal-title-group><issn pub-type="ppub">1010-660X</issn><issn pub-type="epub">1648-9144</issn><?publisher_abbrev mdpi?><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10972505</article-id><article-id pub-id-type="pmcid-ver">PMC10972505.1</article-id><article-id pub-id-type="pmcaid">10972505</article-id><article-id pub-id-type="pmcaiid">10972505</article-id><article-id pub-id-type="pmid">38541191</article-id><article-id pub-id-type="doi">10.3390/medicina60030465</article-id><article-id pub-id-type="publisher-id">medicina-60-00465</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Diagnostic Challenges in Inflammatory Choroidal Neovascularization</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7927-6277</contrib-id><name name-style="western"><surname>Karska-Basta</surname><given-names initials="I">Izabella</given-names></name><xref rid="af1-medicina-60-00465" ref-type="aff">1</xref><xref rid="af2-medicina-60-00465" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pociej-Marciak</surname><given-names initials="W">Weronika</given-names></name><xref rid="af1-medicina-60-00465" ref-type="aff">1</xref><xref rid="af2-medicina-60-00465" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Żuber-Łaskawiec</surname><given-names initials="K">Katarzyna</given-names></name><xref rid="af1-medicina-60-00465" ref-type="aff">1</xref><xref rid="af2-medicina-60-00465" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0943-6575</contrib-id><name name-style="western"><surname>Markiewicz</surname><given-names initials="A">Anna</given-names></name><xref rid="af1-medicina-60-00465" ref-type="aff">1</xref><xref rid="af2-medicina-60-00465" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chrząszcz</surname><given-names initials="M">Michał</given-names></name><xref rid="af2-medicina-60-00465" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Romanowska-Dixon</surname><given-names initials="B">Bożena</given-names></name><xref rid="af1-medicina-60-00465" ref-type="aff">1</xref><xref rid="af2-medicina-60-00465" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2859-4149</contrib-id><name name-style="western"><surname>Kubicka-Trząska</surname><given-names initials="A">Agnieszka</given-names></name><xref rid="af1-medicina-60-00465" ref-type="aff">1</xref><xref rid="af2-medicina-60-00465" ref-type="aff">2</xref><xref rid="c1-medicina-60-00465" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-medicina-60-00465"><label>1</label>Chair of Ophthalmology, Faculty of Medicine, Medical College, Jagiellonian University, Kopernika Str. 38, 31-501 Krakow, Poland; <email>izabella.karska-basta@uj.edu.pl</email> (I.K.-B.); <email>anna.markiewicz@uj.edu.pl</email> (A.M.); </aff><aff id="af2-medicina-60-00465"><label>2</label>Clinic of Ophthalmology and Ocular Oncology, University Hospital, Kopernika Str. 38, 31-501 Krakow, Poland; <email>m.a.chrzaszcz@gmail.com</email></aff><author-notes><corresp id="c1-medicina-60-00465"><label>*</label>Correspondence: <email>agnieszka.kubicka-trzaska@uj.edu.pl</email>; Tel.: +48-604456284</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><volume>60</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">458690</issue-id><elocation-id>465</elocation-id><history><date date-type="received"><day>03</day><month>2</month><year>2024</year></date><date date-type="rev-recd"><day>24</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>08</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-29 18:25:14.503"><day>29</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>© 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medicina-60-00465.pdf"><?pdf-name medicina-60-00465.pdf?><?pdf-size 15487490?><?pdf-md5 ce9221d916d934090165dab6259b627e?><?pdf-image-server-status NEVER_LOAD?><?pdf-cloudpmc-urn urn:app:208f/10972505/ce9221d916d9/medicina-60-00465.pdf?></self-uri><abstract><p>Inflammation plays a key role in the induction of choroidal neovascularization (CNV). Inflammatory choroidal neovascularization (iCNV) is a severe but uncommon complication of both infectious and non-infectious uveitides. It is hypothesized that its pathogenesis is similar to that of wet age-related macular degeneration (AMD), and involves hypoxia as well as the release of vascular endothelial growth factor, stromal cell-derived factor 1-alpha, and other mediators. Inflammatory CNV develops when inflammation or infection directly involves the retinal pigment epithelium (RPE)–Bruch’s membrane complex. Inflammation itself can compromise perfusion, generating a gradient of retinal–choroidal hypoxia that additionally promotes the formation of choroidal neovascularization in the course of uveitis. The development of choroidal neovascularization may be a complication, especially in conditions such as punctate inner choroidopathy, multifocal choroiditis, serpiginous choroiditis, and presumed ocular histoplasmosis syndrome. Although the majority of iCNV cases are well defined and appear as the “classic” type (type 2 lesion) on fluorescein angiography, the diagnosis of iCNV is challenging due to difficulties in differentiating between inflammatory choroiditis lesions and choroidal neovascularization. Modern multimodal imaging, particularly the recently introduced technology of optical coherence tomography (OCT) and OCT angiography (noninvasive and rapid imaging modalities), can reveal additional features that aid the diagnosis of iCNV. However, more studies are needed to establish their role in the diagnosis and evaluation of iCNV activity. </p></abstract><kwd-group><kwd>uveitis</kwd><kwd>inflammatory choroidal neovascularization</kwd><kwd>multimodal imaging</kwd><kwd>fluorescein angiography</kwd><kwd>indocyanine green angiography</kwd><kwd>optical coherence tomography</kwd><kwd>optical coherence tomography angiography</kwd><kwd>near-infrared autofluorescence</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-medicina-60-00465"><title>1. Introduction</title><p>Uveitis-related choroidal neovascularization (CNV), known as inflammatory CNV (iCNV), is an uncommon complication of uveitis. At the same time, it is one of the most severe causes of visual impairment in patients with uveitis [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00465" ref-type="bibr">3</xref>]. Inflammatory CNV is the third cause of CNV following wet age-related macular degeneration (AMD) and pathological myopia [<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00465" ref-type="bibr">3</xref>]. Inflammatory CNV develops more frequently in patients with posterior uveitis (2.7%) and panuveitis (0.8%) as compared with those with anterior and intermediate uveitis (0.1%) [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>]. CNV is a clinically important complication of both infectious and non-infectious uveitis and is found to be more frequent in some specific clinical entities. Its incidence in non-infectious posterior uveitis has been reported to reach 2% [<xref rid="B5-medicina-60-00465" ref-type="bibr">5</xref>]. A higher incidence of CNV was reported in multifocal choroiditis, punctate inner choroidopathy, serpiginous choroidopathy, birdshot retinochoroidopathy, and Vogt–Koyanagi–Harada disease [<xref rid="B6-medicina-60-00465" ref-type="bibr">6</xref>,<xref rid="B7-medicina-60-00465" ref-type="bibr">7</xref>,<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>,<xref rid="B9-medicina-60-00465" ref-type="bibr">9</xref>,<xref rid="B10-medicina-60-00465" ref-type="bibr">10</xref>,<xref rid="B11-medicina-60-00465" ref-type="bibr">11</xref>,<xref rid="B12-medicina-60-00465" ref-type="bibr">12</xref>,<xref rid="B13-medicina-60-00465" ref-type="bibr">13</xref>,<xref rid="B14-medicina-60-00465" ref-type="bibr">14</xref>,<xref rid="B15-medicina-60-00465" ref-type="bibr">15</xref>,<xref rid="B16-medicina-60-00465" ref-type="bibr">16</xref>,<xref rid="B17-medicina-60-00465" ref-type="bibr">17</xref>,<xref rid="B18-medicina-60-00465" ref-type="bibr">18</xref>]. On the other hand, data on the incidence of iCNV secondary to infectious uveitis are scarce and are derived mainly from case series and case reports. The prevalence of iCNV, depending on the etiology of uveitis, is presented in <xref rid="medicina-60-00465-t001" ref-type="table">Table 1</xref>. </p><p>According to Baxter et al. [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>], the presence of epiretinal neovascularization is associated with an over three-fold higher risk of iCNV. Moreover, the risk of CNV was significantly greater in eyes with active inflammation vs. those with inactive inflammation. The presence of anterior chamber cells grade 2+, as defined by the Standardization of Uveitis Nomenclature Working Group, was shown to be associated with iCNV. However, increased vitreous cells and vitreous haze were not significantly associated with an altered risk of incident CNV in patients with uveitis [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>]. A previous diagnosis of CNV in the contralateral eye was associated with a several-fold higher risk of CNV in the second eye. However, the eyes of patients with bilateral uveitis were less likely to develop CNV than the affected eyes of patients with unilateral uveitis [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>]. </p><p>The underlying pathophysiology of iCNV is likely similar to the pathophysiology of CNV in other conditions associated with CNV, such as age-related macular degeneration (AMD) or pathologic myopia. Inflammatory CNV may thus be considered not as a distinct form of CNV, but rather as associated with a set of circumstances that permit its development [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00465" ref-type="bibr">3</xref>].</p><p>It was demonstrated that vascular endothelial growth factor (VEGF) plays a key role in CNV development [<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00465" ref-type="bibr">3</xref>]. Moreover, CNV has an extravascular component consisting of fibroblasts and leukocytes that express C-X-C motif chemokine receptor 4 (CXCR4). Retinal pigment epithelial (RPE) cells showed an increased production of tumor necrosis factor as well as interleukins IL-1, IL-2, IL-6, and IL-10, accounting for the inflammatory component of CNV [<xref rid="B47-medicina-60-00465" ref-type="bibr">47</xref>,<xref rid="B48-medicina-60-00465" ref-type="bibr">48</xref>]. Also, other mediators are involved in CNV development, such as nitric oxide, angiostatin, endostatin, C-C chemokine receptor type 3 (CCR3), and pigment epithelium-derived growth factor (PEDF), contrasting the neovascularization [<xref rid="B49-medicina-60-00465" ref-type="bibr">49</xref>]. </p><p>Recently, D’Ambrosio et al. [<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>], based on the immunohistochemical staining grading of three structures of CNV, namely, the RPE, vascular network, and fibroblasts for SDF1, CXCR4, and VEGF receptor 2, revealed differences in the CXCR4 staining of the vascular meshwork of iCNV as compared with AMD-related CNV, suggesting that capillaries have a different role in membrane development [<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>]. However, because of a low P value for the CXCR4 staining of the vascular meshwork of uveitis-related CNV versus AMD-related CNV, the authors concluded that further studies on this distinctive aspect are necessary [<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>].</p><p>There are two pathophysiological mechanisms by which uveitis can promote the development of iCNV [<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B47-medicina-60-00465" ref-type="bibr">47</xref>]. The first one is associated with inflammation-mediated damage of the RPE-Bruch’s membrane complex, which disrupts the outer blood-retinal barrier and permits neovascular upgrowth from the choroid. The damage can be induced by an angiogenic stimulus mediated by local inflammation, or it can result from a combination of both [<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>]. The imbalance between the inhibitory and stimulatory actions of the soluble mediators produced by the RPE is supposed to be the trigger of neoangiogenesis. Activated inflammatory cells secrete enzymes that damage cells and cause degradation in the Bruch’s membrane. Proangiogenic cytokines released by these inflammatory cells may promote CNV growth through breaks in the membrane and into the sub-RPE space, potentially leading to edema, exudation, hemorrhages, and fibrosis, resulting in profound central vision loss [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>]. Thus, a higher risk of damage to the RPE–Bruch’s membrane complex related to adjacent chorioretinal inflammation may explain the higher incidence of iCNV in patients with panuveitis and posterior uveitis [<xref rid="B50-medicina-60-00465" ref-type="bibr">50</xref>]. It is noteworthy that the RPE is often intact in individuals with iCNV, and a majority of iCNVs are type 2 lesions (“classic” type CNVs) with abnormal growth of the vasculature into the outer retinal space [<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>]. The proposed mechanism of iCNV development is thus the focal breach of the RPE due to infection or inflammation leading to the growth and entry of new vessels into the outer retinal space [<xref rid="B50-medicina-60-00465" ref-type="bibr">50</xref>]. The second theory explains that retinal and choroidal inflammation directly compromises perfusion, generating a gradient of retinal–choroidal hypoxia that promotes the formation of choroidal neovascularization [<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>]. It should also be noted that, in some cases, “idiopathic” choroidal neovascularization may herald the subsequent development of posterior uveitis [<xref rid="B51-medicina-60-00465" ref-type="bibr">51</xref>]. </p><p>Inflammatory CNV is typically diagnosed when a patient with uveitis reports a sudden deterioration of vision and/or metamorphopsias [<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00465" ref-type="bibr">3</xref>,<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B52-medicina-60-00465" ref-type="bibr">52</xref>]. In advanced cases of iCNV, a central scotoma may be present. Some active extrafoveal lesions can be asymptomatic and may be missed initially due to the presence of associated features such as inflammatory lesions, scars, and pigmentation, as well as intra- or subretinal fluid accumulation [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00465" ref-type="bibr">3</xref>,<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>]. In such cases, iCNV may be detected in imaging studies [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B6-medicina-60-00465" ref-type="bibr">6</xref>,<xref rid="B52-medicina-60-00465" ref-type="bibr">52</xref>,<xref rid="B53-medicina-60-00465" ref-type="bibr">53</xref>]. </p><p>Inflammatory CNV lesions typically grow close to the edge of a postinflammatory atrophic chorioretinal scar, although iCNV can rarely be synchronous with an active disease [<xref rid="B52-medicina-60-00465" ref-type="bibr">52</xref>,<xref rid="B53-medicina-60-00465" ref-type="bibr">53</xref>]. Inflammatory CNVs can be subfoveal, extrafoveal, or juxtafoveal, and are highly focal [<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>]. These can be associated with intra- or subretinal hemorrhages and exudations. Inactive iCNV can result in a subretinal yellow-white scar, which may be associated with fibrosis and pigmentation. The presence of intra- or subretinal fluid with iCNV, as well as serous retinal detachment, may also represent signs of inflammation, leading to a misdiagnosis during a basic ophthalmological examination [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B2-medicina-60-00465" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00465" ref-type="bibr">3</xref>,<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>].</p><p>Thus, in patients with posterior uveitis, the identification of iCNV is challenging due to related abnormalities, including choroiditis, chorioretinal scarring, and inflammatory lesions [<xref rid="B52-medicina-60-00465" ref-type="bibr">52</xref>,<xref rid="B53-medicina-60-00465" ref-type="bibr">53</xref>]. Difficulties in a differential diagnosis of iCNV and active inflammatory lesions arise from the characteristic presence of intraretinal or subretinal fluid as well as serous retinal detachment in both [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>,<xref rid="B52-medicina-60-00465" ref-type="bibr">52</xref>]. An accurate characterization of inflammatory lesions is important for the diagnosis of an underlying pathology and the implementation of adequate treatment. </p><p>The aim of this paper was to discuss current multimodal imaging tools for the diagnosis of iCNV, with an emphasis on technological advances and future perspectives.</p></sec><sec id="sec2-medicina-60-00465"><title>2. Imaging Tools for the Detection of iCNV</title><sec id="sec2dot1-medicina-60-00465"><title>2.1. Fluorescein Angiography</title><p>Fluorescein angiography (FA) has been widely employed in the diagnosis of CNV secondary to various ocular pathologies. Since iCNV is often a classic type of neovascular membrane (type 2), it can be visualized by FA. CNV lesions are present on FA as early iso- or hyperfluorescence with late leakage [<xref rid="B54-medicina-60-00465" ref-type="bibr">54</xref>]. Similarly, active inflammatory lesions show features of early isofluorescence (although mostly hypofluorescence) and late leakage, while inactive atrophic lesions are characterized by early hypo- or isofluorescence with late staining (suggesting an RPE window defect) without leakage [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B55-medicina-60-00465" ref-type="bibr">55</xref>,<xref rid="B56-medicina-60-00465" ref-type="bibr">56</xref>] (<xref rid="medicina-60-00465-f001" ref-type="fig">Figure 1</xref> and <xref rid="medicina-60-00465-f002" ref-type="fig">Figure 2</xref>). These highly similar FA features of iCNV and inflammatory lesions pose a diagnostic challenge. In conditions such as multifocal choroiditis, serpiginous choroiditis, or Vogt–Koyanagi–Harada disease, which present with scarring and pigmentation due to extensive retinal involvement, the detection of hyperfluorescence associated with CNV may be particularly difficult [<xref rid="B52-medicina-60-00465" ref-type="bibr">52</xref>,<xref rid="B53-medicina-60-00465" ref-type="bibr">53</xref>,<xref rid="B57-medicina-60-00465" ref-type="bibr">57</xref>]. Thus, FA alone may be insufficient to identify iCNV lesions and initiate appropriate therapy. Therefore, a multimodal approach with additional tests is recommended. </p></sec><sec id="sec2dot2-medicina-60-00465"><title>2.2. Indocyanine Green Angiography</title><p>One of the imaging techniques for the visualization of the choroid is indocyanine green angiography (ICGA), which allows a better visualization of the choroid compared with FA [<xref rid="B58-medicina-60-00465" ref-type="bibr">58</xref>]. ICGA plays an important role in assessing pathologies involving the choroidal vasculature and choriocapillaris in chorioretinal inflammatory diseases. It is helpful in differentiating between iCNV and inflammatory lesions [<xref rid="B59-medicina-60-00465" ref-type="bibr">59</xref>,<xref rid="B60-medicina-60-00465" ref-type="bibr">60</xref>]. ICGA allows us to tell the difference between a recurrent inflammatory focus and iCNV: the former appears as an early hypofluorescent lesion, whereas the latter has been a hyperfluorescent lesion since early angiographic frames [<xref rid="B58-medicina-60-00465" ref-type="bibr">58</xref>,<xref rid="B59-medicina-60-00465" ref-type="bibr">59</xref>]. ICGA is also mandatory in the case of CNV associated with choriocapillaritis, such as multifocal choroiditis (MFC), where it shows the extent of occult choriocapillaris nonperfusion and hence the risk for CNV development [<xref rid="B60-medicina-60-00465" ref-type="bibr">60</xref>,<xref rid="B61-medicina-60-00465" ref-type="bibr">61</xref>]. CNV secondary to MFC is more frequent in inflamed areas; however, this may originate from an old chorioretinal scar as well. Low-grade chronic inflammation can be at the core of this process, and ICGA frequently shows areas of non-perfusion indicating ischemia, which may be the trigger of angiogenesis. In such cases, ICGA is essential in the evaluation of the choroidal status. Importantly, ICGA was shown to outperform FA in detecting occult CNV lesions [<xref rid="B54-medicina-60-00465" ref-type="bibr">54</xref>]. While iCNV is typically a classic lesion that can be easily visualized by FA, ICGA has been recently reported to be more accurate in assessing the size of neovascular lesions, especially in patients with idiopathic CNV, which shares several clinical features with iCNV [<xref rid="B62-medicina-60-00465" ref-type="bibr">62</xref>]. Thus, ICG helps identify both iCNV and inflammatory choroidal alterations in patients with uveitis, allowing clinical differentiation between these lesions and a more comprehensive evaluation of the disease [<xref rid="B60-medicina-60-00465" ref-type="bibr">60</xref>] (<xref rid="medicina-60-00465-f003" ref-type="fig">Figure 3</xref> and <xref rid="medicina-60-00465-f004" ref-type="fig">Figure 4</xref>). </p></sec><sec id="sec2dot3-medicina-60-00465"><title>2.3. Optical Coherence Tomography </title><p>Optical coherence tomography (OCT) is a noninvasive and highly repeatable imaging technique that has revolutionized the management of retinal and choroidal diseases. By providing the quasi-histological sections of the ocular structure, it allows clinicians to identify ocular pathologies and assess response to treatment [<xref rid="B63-medicina-60-00465" ref-type="bibr">63</xref>]. Moreover, the enhanced depth imaging modality of OCT can be used to evaluate choroidal thickness and structural modifications, which is particularly valuable in the treatment of uveitis [<xref rid="B63-medicina-60-00465" ref-type="bibr">63</xref>]. </p><p>Inflammatory CNV usually develops between the RPE and neurosensory retina, demonstrating similar features on OCT imaging as classic (type 2) CNV [<xref rid="B58-medicina-60-00465" ref-type="bibr">58</xref>]. In both cases, the lesions appear as hyperreflective structures located in front of a disrupted RPE, with solid tissue in the subretinal space [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B64-medicina-60-00465" ref-type="bibr">64</xref>,<xref rid="B65-medicina-60-00465" ref-type="bibr">65</xref>,<xref rid="B66-medicina-60-00465" ref-type="bibr">66</xref>]. However, there is a single OCT feature that can help distinguish between iCNV and other classic CNVs. This is the so-called “pitchfork sign”, characterized by finger-like hyperreflective lesions extending from the CNV into the outer retinal layers, and it allows us to differentiate iCNV from other causes of CNV [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B53-medicina-60-00465" ref-type="bibr">53</xref>,<xref rid="B67-medicina-60-00465" ref-type="bibr">67</xref>,<xref rid="B68-medicina-60-00465" ref-type="bibr">68</xref>] (<xref rid="medicina-60-00465-f005" ref-type="fig">Figure 5</xref>). The inflammatory conditions associated with this sign include idiopathic multifocal choroiditis/punctate inner choroidopathy (MFC/PIC), intraocular tuberculosis, and acute syphilitic posterior placoid chorioretinitis [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B53-medicina-60-00465" ref-type="bibr">53</xref>,<xref rid="B67-medicina-60-00465" ref-type="bibr">67</xref>,<xref rid="B68-medicina-60-00465" ref-type="bibr">68</xref>]. Rajabian et al. and Berensztejn et al. reported “pitchfork signs” in patients with choroidal osteoma. The authors proposed that inflammation is the most important stimulus for the development of CNV in these cases [<xref rid="B69-medicina-60-00465" ref-type="bibr">69</xref>,<xref rid="B70-medicina-60-00465" ref-type="bibr">70</xref>]. However, recently, Falavrajani et al. [<xref rid="B71-medicina-60-00465" ref-type="bibr">71</xref>] have described the “pitchfork sign” in five eyes with type 2 CNV and without any sign of ocular inflammation. They speculated that traction of the type 2 CNV complex on the outer retinal layers and consequent dragging of the layers or Müller cell activation could explain the presence of the “pitchfork sign” [<xref rid="B71-medicina-60-00465" ref-type="bibr">71</xref>]. </p><p>It was reported that the OCT features of CNV activity such as retinal thickening, subretinal and intraretinal fluid, intraretinal hyperreflective flecks, and undefined boundaries of subretinal material predicted the presence of FA leakage [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B66-medicina-60-00465" ref-type="bibr">66</xref>] (<xref rid="medicina-60-00465-f006" ref-type="fig">Figure 6</xref>b,g). Thus, it was concluded that OCT can be used for monitoring disease progression and response to treatment [<xref rid="B68-medicina-60-00465" ref-type="bibr">68</xref>,<xref rid="B72-medicina-60-00465" ref-type="bibr">72</xref>].</p><p>Moreover, central retinal thickness evaluated by OCT is often used as an objective measure of iCNV activity [<xref rid="B73-medicina-60-00465" ref-type="bibr">73</xref>,<xref rid="B74-medicina-60-00465" ref-type="bibr">74</xref>,<xref rid="B75-medicina-60-00465" ref-type="bibr">75</xref>]. Recently, Giuffrè et al. [<xref rid="B76-medicina-60-00465" ref-type="bibr">76</xref>] demonstrated increased choroidal thickness under iCNV that decreases after therapy: the so-called “sponge sign” (<xref rid="medicina-60-00465-f007" ref-type="fig">Figure 7</xref>). The authors investigate choroidal thickness changes related to the clinical activity of inflammatory choroidal neovascularization in punctate inner choroidopathy/multifocal choroiditis as compared to myopic choroidal neovascularization. They found that choroidal thickness beneath inflammatory choroidal neovascularization significantly increased at baseline and decreased after therapy, reaching preclinical values. Conversely, no significant choroidal thickness changes were disclosed in myopic choroidal neovascularization eyes, under any location. Thus, OCT-based choroidal thickness evaluation may represent an additional useful tool to monitor inflammatory choroidal neovascularization activity. Moreover, choroidal thickness under CNV could be used to discriminate the origin of the choroidal neovascular membrane in doubtful cases (either inflammatory or myopic) and to guide therapeutic management [<xref rid="B76-medicina-60-00465" ref-type="bibr">76</xref>]. </p><p>OCT images can also help differentiate between iCNV lesions and non-neovascular alterations at the RPE level that are characteristic of several types of uveitis. For example, acute inflammatory foci in multifocal choroiditis show a deeper penetration of the OCT signal, a feature that is usually not seen in iCNV [<xref rid="B56-medicina-60-00465" ref-type="bibr">56</xref>,<xref rid="B65-medicina-60-00465" ref-type="bibr">65</xref>]. However, when distinguishing CNV lesions from iCNV, the use of OCT alone may be limited as these lesions display similar features of outer retinal or RPE hyperreflectivity, intraretinal edema, sub-RPE fluid, and exudation in conditions with the involvement of the RPE or choriocapillaris (e.g., multifocal choroiditis and punctate inner choroidopathy) [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B74-medicina-60-00465" ref-type="bibr">74</xref>,<xref rid="B75-medicina-60-00465" ref-type="bibr">75</xref>,<xref rid="B77-medicina-60-00465" ref-type="bibr">77</xref>,<xref rid="B78-medicina-60-00465" ref-type="bibr">78</xref>]. In such cases, the characteristics of the lesions can be determined by a combination of FA, ICGA, and OCT angiography (OCTA). </p></sec><sec id="sec2dot4-medicina-60-00465"><title>2.4. Optical Coherence Tomography Angiography </title><p>The usefulness of OCTA as a noninvasive technique for the detection of iCNV has been reported by several investigators. Cheng et al. [<xref rid="B79-medicina-60-00465" ref-type="bibr">79</xref>] assessed the ability of OCTA to detect iCNV and differentiate it from inflammatory lesions as compared with conventional FA in 26 patients with multifocal choroiditis. The authors concluded that OCTA outperformed FA in differentiating CNV from inflammatory lesions, as the latter do not show any blood flow signals. It also permitted the visualization of the detailed vascular structure of CNV. Therefore, it could be used as an alternative option for CNV identification and to guide therapeutic decision making [<xref rid="B77-medicina-60-00465" ref-type="bibr">77</xref>]. Similarly, in a recent retrospective study of 14 patients, Zahid et al. [<xref rid="B80-medicina-60-00465" ref-type="bibr">80</xref>] used OCTA to evaluate neovascular flow signals in macular chorioretinal lesions occurring in idiopathic multifocal choroiditis. They concluded that OCTA may be a useful tool for understanding the pathophysiology of the disease and monitoring its course. The utility of OCTA for the noninvasive diagnosis of iCNV and its subsequent follow-up was also confirmed by Yee et al. [<xref rid="B81-medicina-60-00465" ref-type="bibr">81</xref>]. Finally, in a recent study, Aggarwal et al. [<xref rid="B82-medicina-60-00465" ref-type="bibr">82</xref>] investigated the OCTA features of tuberculosis-associated choroiditis in comparison with conventional imaging modalities, including FA, ICGA, and OCTA. This was the first study to demonstrate that OCTA can identify type 1 neovascular networks. The research led to the conclusion that OCTA is indispensable to exclude neovascular networks when FA, ICGA, and OCT results are inconclusive [<xref rid="B81-medicina-60-00465" ref-type="bibr">81</xref>] (<xref rid="medicina-60-00465-f006" ref-type="fig">Figure 6</xref>c–h, <xref rid="medicina-60-00465-f008" ref-type="fig">Figure 8</xref> and <xref rid="medicina-60-00465-f009" ref-type="fig">Figure 9</xref>).</p><p>In patients with posterior uveitis, the identification of iCNV is challenging due to related abnormalities, including associated pathologies such as choroiditis, chorioretinal lesions, and choroidal scarring [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B82-medicina-60-00465" ref-type="bibr">82</xref>,<xref rid="B83-medicina-60-00465" ref-type="bibr">83</xref>]. In such cases, OCTA allows noninvasive diagnostic imaging of iCNV and differentiation from inflammatory pathologies [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B82-medicina-60-00465" ref-type="bibr">82</xref>,<xref rid="B83-medicina-60-00465" ref-type="bibr">83</xref>].</p><p>While the above studies prove the role of OCTA in the diagnosis and follow-up of patients with iCNV, larger prospective studies are needed to determine its advantages over conventional imaging. </p></sec><sec id="sec2dot5-medicina-60-00465"><title>2.5. Near-Infrared Autofluorescence Imaging</title><p>Fundus autofluorescence (FAF) is a valuable imaging tool for multiple anatomical and physiological alterations in the ocular tissue [<xref rid="B84-medicina-60-00465" ref-type="bibr">84</xref>]. Essentially, FAF is a map of lipofuscin distribution, which is the autofluorescent pigment of the eye naturally found in the RPE–photoreceptor complex [<xref rid="B85-medicina-60-00465" ref-type="bibr">85</xref>]. It was reported that iCNV lesions may show a different pattern on FAF imaging than active inflammatory foci [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B84-medicina-60-00465" ref-type="bibr">84</xref>,<xref rid="B85-medicina-60-00465" ref-type="bibr">85</xref>]. In FAF, normal autofluorescence may occur in active iCNV with preserved neurosensory retina [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B83-medicina-60-00465" ref-type="bibr">83</xref>,<xref rid="B84-medicina-60-00465" ref-type="bibr">84</xref>,<xref rid="B85-medicina-60-00465" ref-type="bibr">85</xref>,<xref rid="B86-medicina-60-00465" ref-type="bibr">86</xref>]. Prolonged active CNV tends to present hyperautofluorescence, while hypoautofluorescent areas correlate with photoreceptor and RPE loss [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B83-medicina-60-00465" ref-type="bibr">83</xref>,<xref rid="B86-medicina-60-00465" ref-type="bibr">86</xref>] (<xref rid="medicina-60-00465-f001" ref-type="fig">Figure 1</xref>a and <xref rid="medicina-60-00465-f007" ref-type="fig">Figure 7</xref>b). Active inflammatory foci may show an increased autofluorescence signal [<xref rid="B84-medicina-60-00465" ref-type="bibr">84</xref>,<xref rid="B85-medicina-60-00465" ref-type="bibr">85</xref>] (<xref rid="medicina-60-00465-f003" ref-type="fig">Figure 3</xref>a). Therefore, the technique may be used for differentiating between inflammatory and CNV lesions.</p></sec></sec><sec sec-type="conclusions" id="sec3-medicina-60-00465"><title>3. Conclusions</title><p>The detection of inflammatory CNV remains a challenge due to the presence of choroiditis lesions, scarring, and pigmentation that make it difficult to visualize CNV lesions. Available case reports and case series point to the benefits of using OCTA in combination with conventional imaging modalities such as FA, OCT, and ICGA. This multimodal approach may improve the detection and follow-up of iCNV lesions. OCTA is also an important addition to FA and ICGA in terms of providing important information on retinochoroidal abnormalities associated with uveitis, such as the severity of inflammation or the presence of any vascular changes and focal lesions. It may offer advantages over traditional modalities in the detection of neovascular flow in uveitis, but it should be used as an additional tool rather than a replacement for the existing ones. Also, FAF requires further research to reveal whether this imaging modality can be used to differentiate between iCNV and inflammatory lesions and between AMD-related CNV and CNV related to inflammatory disease. </p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.K.-T.; methodology, A.K.-T., I.K.-B. and W.P.-M.; software, K.Ż.-Ł., A.M. and M.C.; validation, A.K.-T. and B.R.-D.; formal analysis, A.K.-T., I.K.-B. and B.R.-D.; investigation, A.K.-T., I.K.-B. and W.P.-M.; resources, B.R.-D. and A.M.; data curation, K.Ż.-Ł., A.M., M.C. and W.P.-M.; writing—original draft preparation, A.K.-T., I.K.-B. and A.M.; writing—review and editing, A.K.-T., I.K.-B. and B.R.-D.; visualization, W.P.-M., M.C. and K.Ż.-Ł.; supervision, A.K.-T. and B.R.-D.; project administration, I.K.-B. and A.K.-T. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>The patients signed an institutional informed consent for the use of medical records and the publication of this information for research purposes.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data supporting the findings of this study are available upon request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-medicina-60-00465"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Agarwal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Invernizzi</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>R.B.</given-names></name>
<name name-style="western"><surname>Foulsham</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Aggarwal</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Handa</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Agrawal</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Pavesio</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name>
</person-group><article-title>An update on inflammatory choroidal neovascularization: Epidemiology, multimodal imaging, and management</article-title><source>J. Ophthalmic Inflamm. Infect.</source><year>2018</year><volume>8</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s12348-018-0155-6</pub-id><pub-id pub-id-type="pmid">30209691</pub-id><pub-id pub-id-type="pmcid">PMC6135736</pub-id></element-citation></ref><ref id="B2-medicina-60-00465"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dhingra</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Kelly</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Majid</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Bailey</surname><given-names>C.B.</given-names></name>
<name name-style="western"><surname>Dick</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment</article-title><source>Indian. J. Ophthalmol.</source><year>2010</year><volume>58</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.4103/0301-4738.58467</pub-id><pub-id pub-id-type="pmid">20029141</pub-id><pub-id pub-id-type="pmcid">PMC2841372</pub-id></element-citation></ref><ref id="B3-medicina-60-00465"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Neri</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Lettieri</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fortuna</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Manoni</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Giovannini</surname><given-names>A.</given-names></name>
</person-group><article-title>Inflammatory choroidal neovascularization</article-title><source>Middle East. Afr. J. Ophthalmol.</source><year>2009</year><volume>16</volume><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.4103/0974-9233.58422</pub-id><pub-id pub-id-type="pmid">20404991</pub-id><pub-id pub-id-type="pmcid">PMC2855665</pub-id></element-citation></ref><ref id="B4-medicina-60-00465"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Baxter</surname><given-names>S.L.</given-names></name>
<name name-style="western"><surname>Pistilli</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Pujari</surname><given-names>S.S.</given-names></name>
<name name-style="western"><surname>Liesegang</surname><given-names>T.L.</given-names></name>
<name name-style="western"><surname>Suhler</surname><given-names>E.B.</given-names></name>
<name name-style="western"><surname>Thorne</surname><given-names>J.E.</given-names></name>
<name name-style="western"><surname>Foster</surname><given-names>C.S.</given-names></name>
<name name-style="western"><surname>Jabs</surname><given-names>D.A.</given-names></name>
<name name-style="western"><surname>Levy-Clarke</surname><given-names>G.A.</given-names></name>
<name name-style="western"><surname>Nussenblatt</surname><given-names>R.B.</given-names></name>
<etal/>
</person-group><article-title>Risk of choroidal neovascularization among the uveitides</article-title><source>Am. J. Ophthalmol.</source><year>2013</year><volume>156</volume><fpage>468</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2013.04.040</pub-id><pub-id pub-id-type="pmid">23795984</pub-id><pub-id pub-id-type="pmcid">PMC3748230</pub-id></element-citation></ref><ref id="B5-medicina-60-00465"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dreyer</surname><given-names>R.F.</given-names></name>
<name name-style="western"><surname>Gass</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis</article-title><source>Arch. Ophthalmol.</source><year>1984</year><volume>102</volume><fpage>1776</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1001/archopht.1984.01040031440019</pub-id><pub-id pub-id-type="pmid">6508619</pub-id></element-citation></ref><ref id="B6-medicina-60-00465"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Morgan</surname><given-names>C.M.</given-names></name>
<name name-style="western"><surname>Schatz</surname><given-names>H.</given-names></name>
</person-group><article-title>Recurrent Multifocal Choroiditis</article-title><source>Ophthalmology</source><year>1986</year><volume>93</volume><fpage>1138</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(86)33611-X</pub-id><pub-id pub-id-type="pmid">2433660</pub-id></element-citation></ref><ref id="B7-medicina-60-00465"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Brown</surname><given-names>J.</given-names><suffix>Jr.</suffix></name>
<name name-style="western"><surname>Folk</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>C.V.</given-names></name>
<name name-style="western"><surname>Kimura</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome</article-title><source>Ophthalmology</source><year>1996</year><volume>103</volume><fpage>1100</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(96)30561-7</pub-id><pub-id pub-id-type="pmid">8684800</pub-id></element-citation></ref><ref id="B8-medicina-60-00465"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ahnood</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Madhusudhan</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Tsaloumas</surname><given-names>M.D.</given-names></name>
<name name-style="western"><surname>Waheed</surname><given-names>N.K.</given-names></name>
<name name-style="western"><surname>Keane</surname><given-names>P.A.</given-names></name>
<name name-style="western"><surname>Denniston</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Punctate inner choroidopathy: A review</article-title><source>Surv. Ophthalmol.</source><year>2017</year><volume>62</volume><fpage>113</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2016.10.003</pub-id><pub-id pub-id-type="pmid">27751823</pub-id></element-citation></ref><ref id="B9-medicina-60-00465"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kuo</surname><given-names>I.C.</given-names></name>
<name name-style="western"><surname>Cunningham</surname><given-names>E.T.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Ocular neovascularization in patients with uveitis</article-title><source>Int. Ophthalmol. Clin.</source><year>2000</year><volume>40</volume><fpage>111</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1097/00004397-200004000-00009</pub-id><pub-id pub-id-type="pmid">10791260</pub-id></element-citation></ref><ref id="B10-medicina-60-00465"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Saatci</surname><given-names>A.O.</given-names></name>
<name name-style="western"><surname>Ayhan</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Engin Durmaz</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Takes</surname><given-names>O.</given-names></name>
</person-group><article-title>Simultaneous Single Dexamethasone Implant and Ranibizumab Injection in a Case with Active Serpiginous Choroiditis and Choroidal Neovascular Membrane</article-title><source>Case Rep. Ophthalmol.</source><year>2015</year><volume>6</volume><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1159/000442346</pub-id><pub-id pub-id-type="pmid">26955341</pub-id><pub-id pub-id-type="pmcid">PMC4777959</pub-id></element-citation></ref><ref id="B11-medicina-60-00465"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kępka</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Brydak-Godowska</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Ciszewska</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Turczyńska</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ciszek</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kęcik</surname><given-names>D.</given-names></name>
</person-group><article-title>Clinical features, diagnosis and management of serpiginuos choroiditis</article-title><source>Ophthalmol. J.</source><year>2022</year><volume>7</volume><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.5603/OJ.2022.0020</pub-id></element-citation></ref><ref id="B12-medicina-60-00465"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rao</surname><given-names>N.A.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Dustin</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Chee</surname><given-names>S.P.</given-names></name>
<name name-style="western"><surname>Okada</surname><given-names>A.A.</given-names></name>
<name name-style="western"><surname>Khairallah</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Bodaghi</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Lehoang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Accorinti</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mochizuki</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Frequency of distinguishing clinical features in Vogt Koyanagi-Harada disease</article-title><source>Ophthalmology</source><year>2010</year><volume>117</volume><fpage>591</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2009.08.030</pub-id><pub-id pub-id-type="pmid">20036008</pub-id><pub-id pub-id-type="pmcid">PMC2830365</pub-id></element-citation></ref><ref id="B13-medicina-60-00465"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Brucker</surname><given-names>A.J.</given-names></name>
<name name-style="western"><surname>Deglin</surname><given-names>E.A.</given-names></name>
<name name-style="western"><surname>Bene</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Hoffman</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Subretinal Choroidal Neovascularization in Birdshot Retinochoroidopathy</article-title><source>Am. J. Ophthalmol.</source><year>1985</year><volume>99</volume><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(14)75864-7</pub-id><pub-id pub-id-type="pmid">2578252</pub-id></element-citation></ref><ref id="B14-medicina-60-00465"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mehta</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Hariharan</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Ho</surname><given-names>A.C.</given-names></name>
<name name-style="western"><surname>Kempen</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Peripapillary choroidal neovascularization in pars planitis</article-title><source>J. Ophthalmic Inflamm. Infect.</source><year>2013</year><volume>3</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/1869-5760-3-13</pub-id><pub-id pub-id-type="pmid">23514324</pub-id><pub-id pub-id-type="pmcid">PMC3605081</pub-id></element-citation></ref><ref id="B15-medicina-60-00465"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nageeb</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Intermediate Uveitis Complicated by Peripapillary Choroidal Neovascularization</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e31040</fpage><pub-id pub-id-type="doi">10.7759/cureus.31040</pub-id><pub-id pub-id-type="pmid">36475155</pub-id><pub-id pub-id-type="pmcid">PMC9719031</pub-id></element-citation></ref><ref id="B16-medicina-60-00465"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Inagaki</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Harada</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Kiribuchi</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ohashi</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Majima</surname><given-names>J.</given-names></name>
</person-group><article-title>Subfoveal choroidal neovascularization in uveitis</article-title><source>Ophthalmologica</source><year>1996</year><volume>210</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1159/000310714</pub-id><pub-id pub-id-type="pmid">8841071</pub-id></element-citation></ref><ref id="B17-medicina-60-00465"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pagliarini</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Piguet</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Ffytche</surname><given-names>T.J.</given-names></name>
<name name-style="western"><surname>Bird</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Foveal involvement and lack of visual recovery in APMPPE associated with uncommon features</article-title><source>Eye</source><year>1995</year><volume>9</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/eye.1995.6</pub-id><pub-id pub-id-type="pmid">7713249</pub-id></element-citation></ref><ref id="B18-medicina-60-00465"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bowie</surname><given-names>E.M.</given-names></name>
<name name-style="western"><surname>Sletten</surname><given-names>K.R.</given-names></name>
<name name-style="western"><surname>Kayser</surname><given-names>D.L.</given-names></name>
<name name-style="western"><surname>Folk</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>James</surname><given-names>C.</given-names></name>
</person-group><article-title>Acute Posterior Multifocal Placoid Pigment Epitheliopathy And Choroidal Neovascularization</article-title><source>Retina</source><year>2005</year><volume>25</volume><fpage>362</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1097/00006982-200504000-00018</pub-id><pub-id pub-id-type="pmid">15805916</pub-id></element-citation></ref><ref id="B19-medicina-60-00465"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Saatci</surname><given-names>A.O.</given-names></name>
<name name-style="western"><surname>Ayhan</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Ipek</surname><given-names>S.C.</given-names></name>
<name name-style="western"><surname>Soylev Bajin</surname><given-names>M.</given-names></name>
</person-group><article-title>Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia</article-title><source>Turk. J. Ophthalmol.</source><year>2018</year><volume>48</volume><fpage>209</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.4274/tjo.09076</pub-id><pub-id pub-id-type="pmid">30202619</pub-id><pub-id pub-id-type="pmcid">PMC6126105</pub-id></element-citation></ref><ref id="B20-medicina-60-00465"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rouvas</surname><given-names>A.A.</given-names></name>
<name name-style="western"><surname>Ladas</surname><given-names>I.D.</given-names></name>
<name name-style="western"><surname>Papakostas</surname><given-names>T.D.</given-names></name>
<name name-style="western"><surname>Moschos</surname><given-names>M.M.</given-names></name>
<name name-style="western"><surname>Vergados</surname><given-names>I.</given-names></name>
</person-group><article-title>Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to multiple evanescent white dot syndrome</article-title><source>Eur. J. Ophthalmol.</source><year>2007</year><volume>17</volume><fpage>996</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1177/112067210701700623</pub-id><pub-id pub-id-type="pmid">18050132</pub-id></element-citation></ref><ref id="B21-medicina-60-00465"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Burova</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Stepanov</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Almesmary</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Jiraskova</surname><given-names>N.</given-names></name>
</person-group><article-title>Choroidal neovascularization in a patient after resolution of multiple evanescent white dot syndrome: A case report</article-title><source>Clin. Case Rep.</source><year>2022</year><volume>10</volume><fpage>e05802</fpage><pub-id pub-id-type="doi">10.1002/ccr3.5802</pub-id><pub-id pub-id-type="pmid">35600039</pub-id><pub-id pub-id-type="pmcid">PMC9107924</pub-id></element-citation></ref><ref id="B22-medicina-60-00465"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>T.Y.A.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>A.Y.</given-names></name>
<name name-style="western"><surname>Wenick</surname><given-names>A.</given-names></name>
</person-group><article-title>Evolution of Choroidal Neovascularization due to Presumed Ocular Histoplasmosis Syndrome on Multimodal Imaging including Optical Coherence Tomography Angiography</article-title><source>Case Rep. Ophthalmol. Med.</source><year>2018</year><volume>2018</volume><fpage>4098419</fpage><pub-id pub-id-type="doi">10.1155/2018/4098419</pub-id><pub-id pub-id-type="pmid">29651354</pub-id><pub-id pub-id-type="pmcid">PMC5830978</pub-id></element-citation></ref><ref id="B23-medicina-60-00465"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Hoang</surname><given-names>Q.V.</given-names></name>
<name name-style="western"><surname>Chau</surname><given-names>F.Y.</given-names></name>
<name name-style="western"><surname>Blair</surname><given-names>M.P.</given-names></name>
<name name-style="western"><surname>Lim</surname><given-names>J.I.</given-names></name>
</person-group><article-title>Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis</article-title><source>Retin. Cases Brief. Rep.</source><year>2014</year><volume>8</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1097/ICB.0b013e3182a48bcc</pub-id><pub-id pub-id-type="pmid">25372202</pub-id></element-citation></ref><ref id="B24-medicina-60-00465"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nielsen</surname><given-names>J.S.</given-names></name>
<name name-style="western"><surname>Fick</surname><given-names>T.A.</given-names></name>
<name name-style="western"><surname>Saggau</surname><given-names>D.D.</given-names></name>
<name name-style="western"><surname>Barnes</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome</article-title><source>Retina</source><year>2012</year><volume>32</volume><fpage>468</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e318229b220</pub-id><pub-id pub-id-type="pmid">21817958</pub-id></element-citation></ref><ref id="B25-medicina-60-00465"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Walia</surname><given-names>H.S.</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>G.K.</given-names></name>
<name name-style="western"><surname>Blinder</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection</article-title><source>Can. J. Ophthalmol.</source><year>2016</year><volume>51</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.jcjo.2015.11.007</pub-id><pub-id pub-id-type="pmid">27085265</pub-id></element-citation></ref><ref id="B26-medicina-60-00465"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zonnevylle</surname><given-names>K.E.</given-names></name>
<name name-style="western"><surname>Stanescu-Segall</surname><given-names>D.</given-names></name>
</person-group><article-title>Intravitreal Bevacizumab for Treatment of Bilateral Candida Chorioretinitis Complicated with Choroidal Neovascularization</article-title><source>Ocul. Immunol. Inflamm.</source><year>2020</year><volume>28</volume><fpage>39</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1080/09273948.2019.1623268</pub-id><pub-id pub-id-type="pmid">31415218</pub-id></element-citation></ref><ref id="B27-medicina-60-00465"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jampol</surname><given-names>L.M.</given-names></name>
<name name-style="western"><surname>Sung</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Walker</surname><given-names>J.D.</given-names></name>
<name name-style="western"><surname>Folk</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>Townsend-Pico</surname><given-names>W.A.</given-names></name>
<name name-style="western"><surname>Lowder</surname><given-names>C.Y.</given-names></name>
<name name-style="western"><surname>Dodds</surname><given-names>E.M.</given-names></name>
<name name-style="western"><surname>Westrich</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Terry</surname><given-names>J.</given-names></name>
</person-group><article-title>Choroidal neovascularization secondary to Candida albicans chorioretinitis</article-title><source>Am. J. Ophthalmol.</source><year>1996</year><volume>121</volume><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(14)70630-0</pub-id><pub-id pub-id-type="pmid">8644807</pub-id></element-citation></ref><ref id="B28-medicina-60-00465"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Makragiannis</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Vahdani</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Carreño</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>R.W.J.</given-names></name>
<name name-style="western"><surname>Dick</surname><given-names>A.D.</given-names></name>
<name name-style="western"><surname>Ross</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis</article-title><source>Int. Ophthalmol.</source><year>2018</year><volume>38</volume><fpage>781</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1007/s10792-017-0502-x</pub-id><pub-id pub-id-type="pmid">28361379</pub-id></element-citation></ref><ref id="B29-medicina-60-00465"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Fine</surname><given-names>S.L.</given-names></name>
<name name-style="western"><surname>Owens</surname><given-names>S.L.</given-names></name>
<name name-style="western"><surname>Haller</surname><given-names>J.A.</given-names></name>
<name name-style="western"><surname>Knox</surname><given-names>D.L.</given-names></name>
<name name-style="western"><surname>Patz</surname><given-names>A.</given-names></name>
</person-group><article-title>Choroidal neovascularization as a late complication of ocular toxoplasmosis</article-title><source>Am. J. Ophthalmol.</source><year>1981</year><volume>91</volume><fpage>318</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/0002-9394(81)90283-X</pub-id><pub-id pub-id-type="pmid">6163361</pub-id></element-citation></ref><ref id="B30-medicina-60-00465"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Willerson</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Aaberg</surname><given-names>T.M.</given-names></name>
<name name-style="western"><surname>Reeser</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Meredith</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Unusual ocular presentation of acute toxoplasmosis</article-title><source>Br. J. Ophthalmol.</source><year>1977</year><volume>61</volume><fpage>693</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1136/bjo.61.11.693</pub-id><pub-id pub-id-type="pmid">588525</pub-id><pub-id pub-id-type="pmcid">PMC1043099</pub-id></element-citation></ref><ref id="B31-medicina-60-00465"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Benevento</surname><given-names>J.D.</given-names></name>
<name name-style="western"><surname>Jager</surname><given-names>R.D.</given-names></name>
<name name-style="western"><surname>Noble</surname><given-names>A.G.</given-names></name>
<name name-style="western"><surname>Latkany</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Mieler</surname><given-names>W.F.</given-names></name>
<name name-style="western"><surname>Sautter</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Meyers</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Mets</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Grassi</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Rabiah</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Toxoplasmosis Study Group. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy</article-title><source>Arch. Ophthalmol.</source><year>2008</year><volume>126</volume><fpage>1152</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1001/archopht.126.8.1152</pub-id><pub-id pub-id-type="pmid">18695115</pub-id><pub-id pub-id-type="pmcid">PMC2741687</pub-id></element-citation></ref><ref id="B32-medicina-60-00465"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sienicka</surname><given-names>P.</given-names></name>
</person-group><article-title>Eye toxoplasmosis complicated by choroidal neovascularization effectively treated with the anti-vascular endothelial growth factor aflibercept</article-title><source>Klin. Ocz.</source><year>2022</year><volume>124</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.5114/ko.2022.116832</pub-id></element-citation></ref><ref id="B33-medicina-60-00465"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lampariello</surname><given-names>D.A.</given-names></name>
<name name-style="western"><surname>Primo</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Ocular toxocariasis: A rare presentation of a posterior pole granuloma with an associated choroidal neovascular membrane</article-title><source>J. Am. Optom. Assoc.</source><year>1999</year><volume>70</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">10457701</pub-id></element-citation></ref><ref id="B34-medicina-60-00465"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lyall</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Hutchison</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Gaskell</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Varikkara</surname><given-names>M.</given-names></name>
</person-group><article-title>Intravitreal Ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy</article-title><source>Eye</source><year>2010</year><volume>24</volume><fpage>1730</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1038/eye.2010.131</pub-id><pub-id pub-id-type="pmid">20930857</pub-id></element-citation></ref><ref id="B35-medicina-60-00465"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yoon</surname><given-names>D.Y.</given-names></name>
<name name-style="western"><surname>Woo</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Intravitreal Administration of Ranibizumab and Bevacizumab for Choroidal Neovascularization Secondary to Ocular Toxocariasis: A Case Report</article-title><source>Ocular Immunol. Inflamm.</source><year>2018</year><volume>26</volume><fpage>639</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1080/09273948.2016.1239744</pub-id><pub-id pub-id-type="pmid">27775459</pub-id></element-citation></ref><ref id="B36-medicina-60-00465"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chung</surname><given-names>Y.M.</given-names></name>
<name name-style="western"><surname>Yeh</surname><given-names>T.S.</given-names></name>
<name name-style="western"><surname>Sheu</surname><given-names>S.J.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Macular subretinal neovascularization in choroidal tuberculosis</article-title><source>Ann. Ophthalmol.</source><year>1989</year><volume>21</volume><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">2475047</pub-id></element-citation></ref><ref id="B37-medicina-60-00465"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lee Kim</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Rodger</surname><given-names>D.C.</given-names></name>
<name name-style="western"><surname>Rao</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Choroidal neovascularization secondary to tuberculosis: Presentation and management</article-title><source>Am. J. Ophthalmol. Case Rep.</source><year>2017</year><volume>6</volume><fpage>124</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.ajoc.2016.12.025</pub-id><pub-id pub-id-type="pmcid">PMC5758031</pub-id><pub-id pub-id-type="pmid">29503964</pub-id></element-citation></ref><ref id="B38-medicina-60-00465"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>Y.K.</given-names></name>
<name name-style="western"><surname>Fu</surname><given-names>H.Y.</given-names></name>
<name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name>
<name name-style="western"><surname>Bai</surname><given-names>H.Z.</given-names></name>
</person-group><article-title>Concurrent tuberculous chorioretinitis with choroidal neovascularization and tuberculous meningitis: A case report</article-title><source>BMC Ophthalmol.</source><year>2020</year><volume>20</volume><elocation-id>227</elocation-id><pub-id pub-id-type="doi">10.1186/s12886-020-01504-y</pub-id><pub-id pub-id-type="pmid">32532239</pub-id><pub-id pub-id-type="pmcid">PMC7291746</pub-id></element-citation></ref><ref id="B39-medicina-60-00465"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Interlandi</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Pellegrini</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Pavesio</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>De Luca</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>De Marco</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Papayannis</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Mandarà</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Cuna</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Cirone</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Ciabattoni</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Intraocular Tuberculosis: A Challenging Case Mimicking Wet Age-Related Macular Degeneration</article-title><source>Case Rep. Ophthalmol.</source><year>2021</year><volume>12</volume><fpage>519</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1159/000512578</pub-id><pub-id pub-id-type="pmid">34248585</pub-id><pub-id pub-id-type="pmcid">PMC8255741</pub-id></element-citation></ref><ref id="B40-medicina-60-00465"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Deutman</surname><given-names>A.F.</given-names></name>
<name name-style="western"><surname>Grizzard</surname><given-names>W.S.</given-names></name>
</person-group><article-title>Rubella retinopathy and subretinal neovascularization</article-title><source>Am. J. Ophthalmol.</source><year>1978</year><volume>85</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(14)76670-X</pub-id><pub-id pub-id-type="pmid">619689</pub-id></element-citation></ref><ref id="B41-medicina-60-00465"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Parodi</surname><given-names>M.B.</given-names></name>
<name name-style="western"><surname>Romano</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Montagna</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Bandello</surname><given-names>F.</given-names></name>
</person-group><article-title>Large choroidal excavation in a patient with rubella retinopathy</article-title><source>Eur. J. Ophthalmol.</source><year>2018</year><volume>28</volume><fpage>251</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.5301/ejo.5001056</pub-id><pub-id pub-id-type="pmid">29077180</pub-id></element-citation></ref><ref id="B42-medicina-60-00465"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dewan</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Hasan</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Aron</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Chawla</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Sundar</surname><given-names>D.</given-names></name>
</person-group><article-title>Rubella retinopathy with choroidal neovascular membrane in a 7-year-old</article-title><source>Indian J. Ophthalmol.</source><year>2020</year><volume>68</volume><fpage>1176</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.4103/ijo.IJO_1469_19</pub-id><pub-id pub-id-type="pmid">32461467</pub-id><pub-id pub-id-type="pmcid">PMC7508066</pub-id></element-citation></ref><ref id="B43-medicina-60-00465"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hirano</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Tanikawa</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Miyake</surname><given-names>Y.</given-names></name>
</person-group><article-title>Neovascular maculopathy associated with rubella retinopathy</article-title><source>Jpn. J. Ophthalmol.</source><year>2000</year><volume>44</volume><fpage>697</fpage><pub-id pub-id-type="doi">10.1016/S0021-5155(00)00266-5</pub-id><pub-id pub-id-type="pmid">11094210</pub-id></element-citation></ref><ref id="B44-medicina-60-00465"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Khairallah</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ben Yahia</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Attia</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Jelliti</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Zaouali</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ladjimi</surname><given-names>A.</given-names></name>
</person-group><article-title>Severe ischemic maculopathy in a patient with West Nile virus infection</article-title><source>Ophthalmic Surg. Lasers Imaging</source><year>2006</year><volume>37</volume><fpage>240</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.3928/15428877-20060501-11</pub-id><pub-id pub-id-type="pmid">16749263</pub-id></element-citation></ref><ref id="B45-medicina-60-00465"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Seth</surname><given-names>R.K.</given-names></name>
<name name-style="western"><surname>Stoessel</surname><given-names>K.M.</given-names></name>
<name name-style="western"><surname>Adelman</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Choroidal neovascularization associated with West Nile virus chorioretinitis</article-title><source>Semin. Ophthalmol.</source><year>2007</year><volume>22</volume><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1080/08820530701418375</pub-id><pub-id pub-id-type="pmid">17564926</pub-id></element-citation></ref><ref id="B46-medicina-60-00465"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zito</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Micelli Ferrari</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Di Pilato</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Lorusso</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ferretta</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Ferrari</surname><given-names>L.M.</given-names></name>
<name name-style="western"><surname>Accorinti</surname><given-names>M.</given-names></name>
</person-group><article-title>Clinical course of choroidal neovascular membrane in West Nile virus chorioretinitis: A case report</article-title><source>J. Med. Case Rep.</source><year>2021</year><volume>15</volume><fpage>206</fpage><pub-id pub-id-type="doi">10.1186/s13256-021-02700-0</pub-id><pub-id pub-id-type="pmid">33875008</pub-id><pub-id pub-id-type="pmcid">PMC8056646</pub-id></element-citation></ref><ref id="B47-medicina-60-00465"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Campa</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Costagliola</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Incorvaia</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Sheridan</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Semeraro</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>De Nadai</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Sebastiani</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Parmeggiani</surname><given-names>F.</given-names></name>
</person-group><article-title>Inflammatory mediators and angiogenic factors in choroidal neovascularization: Pathogenetic interactions and therapeutic implications</article-title><source>Mediators Inflamm.</source><year>2010</year><volume>2010</volume><fpage>546826</fpage><pub-id pub-id-type="doi">10.1155/2010/546826</pub-id><pub-id pub-id-type="pmid">20871825</pub-id><pub-id pub-id-type="pmcid">PMC2943126</pub-id></element-citation></ref><ref id="B48-medicina-60-00465"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>D’Ambrosio</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Tortorella</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Iannetti</surname><given-names>L.</given-names></name>
</person-group><article-title>Management of uveitis-related choroidal neovascularization: From the pathogenesis to the therapy</article-title><source>J. Ophthalmol.</source><year>2014</year><volume>2014</volume><fpage>450428</fpage><pub-id pub-id-type="doi">10.1155/2014/450428</pub-id><pub-id pub-id-type="pmid">24868454</pub-id><pub-id pub-id-type="pmcid">PMC4020300</pub-id></element-citation></ref><ref id="B49-medicina-60-00465"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cerquaglia</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Fardeau</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Cagini</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Fiore</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>LeHoang</surname><given-names>P.</given-names></name>
</person-group><article-title>Inflammatory Choroidal Neovascularization: Beyond the Intravitreal Approach</article-title><source>Ocul. Immunol. Inflamm.</source><year>2018</year><volume>26</volume><fpage>1047</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1080/09273948.2017.1311923</pub-id><pub-id pub-id-type="pmid">28471283</pub-id></element-citation></ref><ref id="B50-medicina-60-00465"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sato</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Takeda</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Hasegawa</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Jo</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Arima</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Oshima</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ryoji</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Nakazawa</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Yuzawa</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Nakashizuka</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Interleukin-6 plays a crucial role in the development of subretinal fibrosis in a mouse model</article-title><source>Immunol. Med.</source><year>2018</year><volume>41</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1080/09114300.2018.1451609</pub-id><pub-id pub-id-type="pmid">30938258</pub-id></element-citation></ref><ref id="B51-medicina-60-00465"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tatar</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Adam</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Shinoda</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Stalmans</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Eckardt</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Lüke</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Bartz-Schmidt</surname><given-names>K.U.</given-names></name>
<name name-style="western"><surname>Grisanti</surname><given-names>S.</given-names></name>
</person-group><article-title>Expression of VEGF and PEDF in Choroidal Neovascular Membranes Following Verteporfin Photodynamic Therapy</article-title><source>Am. J. Ophthalmol.</source><year>2006</year><volume>142</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2006.01.085</pub-id><pub-id pub-id-type="pmid">16815256</pub-id></element-citation></ref><ref id="B52-medicina-60-00465"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cunningham</surname><given-names>E.T.</given-names><suffix>Jr.</suffix></name>
<name name-style="western"><surname>Pichi</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Dolz-Marco</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Freund</surname><given-names>K.B.</given-names></name>
<name name-style="western"><surname>Zierhut</surname><given-names>M.</given-names></name>
</person-group><article-title>Inflammatory Choroidal Neovascularization</article-title><source>Ocul. Immunol. Inflamm.</source><year>2020</year><volume>28</volume><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/09273948.2019.1704153</pub-id><pub-id pub-id-type="pmid">32004111</pub-id></element-citation></ref><ref id="B53-medicina-60-00465"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bou Ghanem</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Neri</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Dolz-Marco</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Albini</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Fawzi</surname><given-names>A.</given-names></name>
</person-group><article-title>Review for Diagnostics of the Year: Inflammatory Choroidal Neovascularization-Imaging Update</article-title><source>Ocul. Immunol. Inflamm.</source><year>2023</year><volume>31</volume><fpage>819</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1080/09273948.2022.2046793</pub-id><pub-id pub-id-type="pmid">35404739</pub-id></element-citation></ref><ref id="B54-medicina-60-00465"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Machida</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Fujiwara</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Murai</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Kubo</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kurosaka</surname><given-names>D.</given-names></name>
</person-group><article-title>Idiopathic choroidal neovascularization as an early manifestation of inflammatory chorioretinal diseases</article-title><source>Retina</source><year>2008</year><volume>28</volume><fpage>703</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e318160798f</pub-id><pub-id pub-id-type="pmid">18463513</pub-id></element-citation></ref><ref id="B55-medicina-60-00465"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bansal</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Bansal</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Dogra</surname><given-names>M.R.</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Katoch</surname><given-names>D.</given-names></name>
</person-group><article-title>Diagnostic challenges in inflammatory choroidal neovascular membranes</article-title><source>Ocul. Immunol. Inflamm.</source><year>2017</year><volume>25</volume><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.3109/09273948.2016.1160128</pub-id><pub-id pub-id-type="pmid">27082010</pub-id></element-citation></ref><ref id="B56-medicina-60-00465"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Atmaca</surname><given-names>L.S.</given-names></name>
<name name-style="western"><surname>Batioğlu</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Atmaca</surname><given-names>P.</given-names></name>
</person-group><article-title>Evaluation of choroidal neovascularization in age-related macular degeneration with fluorescein and indocyanine green videoangiography</article-title><source>Ophthalmologica</source><year>1996</year><volume>210</volume><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1159/000310695</pub-id><pub-id pub-id-type="pmid">8738457</pub-id></element-citation></ref><ref id="B57-medicina-60-00465"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kotsolis</surname><given-names>A.I.</given-names></name>
<name name-style="western"><surname>Killian</surname><given-names>F.A.</given-names></name>
<name name-style="western"><surname>Ladas</surname><given-names>I.D.</given-names></name>
<name name-style="western"><surname>Yannuzzi</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Fluorescein angiography and optical coherence tomography concordance for choroidal neovascularisation in multifocal choroidtis</article-title><source>Br. J. Ophthalmol.</source><year>2010</year><volume>94</volume><fpage>1506</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1136/bjo.2009.159913</pub-id><pub-id pub-id-type="pmid">20472744</pub-id></element-citation></ref><ref id="B58-medicina-60-00465"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Spaide</surname><given-names>R.F.</given-names></name>
<name name-style="western"><surname>Goldberg</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Freund</surname><given-names>K.B.</given-names></name>
</person-group><article-title>Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging</article-title><source>Retina</source><year>2013</year><volume>33</volume><fpage>1315</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e318286cc77</pub-id><pub-id pub-id-type="pmid">23584703</pub-id></element-citation></ref><ref id="B59-medicina-60-00465"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Perentes</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Van Tran</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Sickenberg</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Herbort</surname><given-names>C.P.</given-names></name>
</person-group><article-title>Subretinal neovascular membranes complicating uveitis: Frequency, treatments, and visual outcome</article-title><source>Ocul. Immunol. Inflamm.</source><year>2005</year><volume>13</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1080/09273940490518883</pub-id><pub-id pub-id-type="pmid">16019682</pub-id></element-citation></ref><ref id="B60-medicina-60-00465"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bischoff</surname><given-names>P.M.</given-names></name>
<name name-style="western"><surname>Flower</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Ten years’ experience with choroidal angiography using indocyanine green dye: A new routine examination or an epilogue?</article-title><source>Doc. Ophthalmol.</source><year>1985</year><volume>60</volume><fpage>235</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/BF00157827</pub-id><pub-id pub-id-type="pmid">2414083</pub-id></element-citation></ref><ref id="B61-medicina-60-00465"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Agrawal</surname><given-names>R.V.</given-names></name>
<name name-style="western"><surname>Biswas</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Gunasekaran</surname><given-names>D.</given-names></name>
</person-group><article-title>Indocyanine green angiography in posterior uveitis</article-title><source>Indian J. Ophthalmol.</source><year>2013</year><volume>61</volume><fpage>148</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.4103/0301-4738.112159</pub-id><pub-id pub-id-type="pmid">23685486</pub-id><pub-id pub-id-type="pmcid">PMC3714951</pub-id></element-citation></ref><ref id="B62-medicina-60-00465"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Herbort</surname><given-names>C.P.</given-names></name>
</person-group><article-title>Fluorescein and indocyanine green angiography for uveitis</article-title><source>Middle East. Afr. J. Ophthalmol.</source><year>2009</year><volume>16</volume><fpage>168</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.4103/0974-9233.58419</pub-id><pub-id pub-id-type="pmid">20404985</pub-id><pub-id pub-id-type="pmcid">PMC2855659</pub-id></element-citation></ref><ref id="B63-medicina-60-00465"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sulzbacher</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Kiss</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Munk</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Deak</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Sacu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Schmidt-Erfurth</surname><given-names>U.</given-names></name>
</person-group><article-title>Diagnostic evaluation of type 2 (classic) choroidal neovascularization: Optical coherence tomography, indocyanine green angiography, and fluorescein angiography</article-title><source>Am. J. Ophthalmol.</source><year>2011</year><volume>152</volume><fpage>799</fpage><lpage>806.e1</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2011.04.011</pub-id><pub-id pub-id-type="pmid">21742302</pub-id></element-citation></ref><ref id="B64-medicina-60-00465"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rush</surname><given-names>R.B.</given-names></name>
<name name-style="western"><surname>Rush</surname><given-names>S.W.</given-names></name>
</person-group><article-title>Evaluation of idiopathic choroidal neovascularization with indocyanine green angiography in patients undergoing bevacizumab therapy</article-title><source>J. Ophthalmol.</source><year>2015</year><volume>2015</volume><fpage>642624</fpage><pub-id pub-id-type="doi">10.1155/2015/642624</pub-id><pub-id pub-id-type="pmid">26113990</pub-id><pub-id pub-id-type="pmcid">PMC4465762</pub-id></element-citation></ref><ref id="B65-medicina-60-00465"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mrejen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Spaide</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Optical coherence tomography: Imaging of the choroid and beyond</article-title><source>Surv. Ophthalmol.</source><year>2013</year><volume>58</volume><fpage>387</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2012.12.001</pub-id><pub-id pub-id-type="pmid">23916620</pub-id></element-citation></ref><ref id="B66-medicina-60-00465"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Amer</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Priel</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Kramer</surname><given-names>M.</given-names></name>
</person-group><article-title>Spectral-domain optical coherence tomographic features of choroidal neovascular membranes in multifocal choroiditis and punctate inner choroidopathy</article-title><source>Graefes Arch. Clin. Exp. Ophthalmol.</source><year>2015</year><volume>253</volume><fpage>949</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1007/s00417-015-2930-5</pub-id><pub-id pub-id-type="pmid">25631844</pub-id></element-citation></ref><ref id="B67-medicina-60-00465"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hoang</surname><given-names>Q.V.</given-names></name>
<name name-style="western"><surname>Cunningham</surname><given-names>E.T.</given-names><suffix>Jr.</suffix></name>
<name name-style="western"><surname>Sorenson</surname><given-names>J.A.</given-names></name>
<name name-style="western"><surname>Freund</surname><given-names>K.B.</given-names></name>
</person-group><article-title>The “pitchfork sign” a distinctive optical coherence tomography finding in inflammatory choroidal neovascularization</article-title><source>Retina</source><year>2013</year><volume>33</volume><fpage>1049</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e31827e25b8</pub-id><pub-id pub-id-type="pmid">23514797</pub-id></element-citation></ref><ref id="B68-medicina-60-00465"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Christakopoulos</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Munch</surname><given-names>I.</given-names></name>
</person-group><article-title>The ‘pitchfork sign’ on optical coherence tomography in a case of acute syphilitic posterior placoid chorioretinitis</article-title><source>Acta Ophthalmol.</source><year>2019</year><volume>97</volume><fpage>e942</fpage><lpage>e943</lpage><pub-id pub-id-type="doi">10.1111/aos.14094</pub-id><pub-id pub-id-type="pmid">30900828</pub-id></element-citation></ref><ref id="B69-medicina-60-00465"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rajabian</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Arrigo</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Grazioli</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Sperti</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bandello</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Battaglia Parodi</surname><given-names>M.</given-names></name>
</person-group><article-title>Focal choroidal excavation and pitchfork sign in choroidal neovascularization associated with choroidal osteoma</article-title><source>Eur. J. Ophthalmol.</source><year>2021</year><volume>31</volume><fpage>NP67</fpage><lpage>NP70</lpage><pub-id pub-id-type="doi">10.1177/1120672119892802</pub-id><pub-id pub-id-type="pmid">31813301</pub-id></element-citation></ref><ref id="B70-medicina-60-00465"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Berensztejn</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Brasil</surname><given-names>O.F.</given-names></name>
</person-group><article-title>Re: The ’pitchfork sign’ a distinctive optical coherence tomography finding in inflammatory choroidal neovascularization</article-title><source>Retina</source><year>2015</year><volume>35</volume><fpage>e23</fpage><lpage>e24</lpage><pub-id pub-id-type="pmid">25699507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IAE.0000000000000565</pub-id><pub-id pub-id-type="pmcid">PMC4975298</pub-id></element-citation></ref><ref id="B71-medicina-60-00465"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Falavarjani</surname><given-names>K.G.</given-names></name>
<name name-style="western"><surname>Au</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Anvari</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Molaei</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ghasemizadeh</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Tsui</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Sadda</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sarraf</surname><given-names>D.</given-names></name>
</person-group><article-title>En face OCT of Type 2 neovascularization: A reappraisal of the pitchfork sign</article-title><source>Ophthalmic Surg. Lasers Imaging Retin.</source><year>2019</year><volume>50</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.3928/23258160-20191031-07</pub-id><pub-id pub-id-type="pmid">31755971</pub-id></element-citation></ref><ref id="B72-medicina-60-00465"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Roy</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Saurabh</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Bansal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Majumdar</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Paul</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor</article-title><source>Indian J. Ophthalmol.</source><year>2017</year><volume>65</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.4103/ijo.IJO_262_16</pub-id><pub-id pub-id-type="pmid">28513493</pub-id><pub-id pub-id-type="pmcid">PMC5452581</pub-id></element-citation></ref><ref id="B73-medicina-60-00465"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mansour</surname><given-names>A.M.</given-names></name>
<name name-style="western"><surname>Mackensen</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Arevalo</surname><given-names>J.F.</given-names></name>
<name name-style="western"><surname>Ziemssen</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Mahendradas</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Mehio-Sibai</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Hrisomalos</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Lai</surname><given-names>T.Y.</given-names></name>
<name name-style="western"><surname>Dodwell</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Chan</surname><given-names>W.M.</given-names></name>
<etal/>
</person-group><article-title>Intravitreal bevacizumab in inflammatory ocular neovascularization</article-title><source>Am. J. Ophthalmol.</source><year>2008</year><volume>146</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2008.05.024</pub-id><pub-id pub-id-type="pmid">18619571</pub-id></element-citation></ref><ref id="B74-medicina-60-00465"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Karti</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Ipek</surname><given-names>S.C.</given-names></name>
<name name-style="western"><surname>Ates</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Saatci</surname><given-names>A.O.</given-names></name>
</person-group><article-title>Inflammatory Choroidal Neovascular Membranes in Patients with Noninfectious Uveitis: The Place of Intravitreal Anti-VEGF Therapy</article-title><source>Med. Hypothesis Discov. Innov. Ophthalmol.</source><year>2020</year><volume>9</volume><fpage>118</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">32490018</pub-id><pub-id pub-id-type="pmcid">PMC7134246</pub-id></element-citation></ref><ref id="B75-medicina-60-00465"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mansour</surname><given-names>A.M.</given-names></name>
<name name-style="western"><surname>Arevalo</surname><given-names>J.F.</given-names></name>
<name name-style="western"><surname>Ziemssen</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Mehio-Sibai</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Mackensen</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Adan</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Chan</surname><given-names>W.-M.</given-names></name>
<name name-style="western"><surname>Ness</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Banker</surname><given-names>A.S.</given-names></name>
<name name-style="western"><surname>Dodwell</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization</article-title><source>Am. J. Ophthalmol.</source><year>2009</year><volume>148</volume><fpage>310</fpage><lpage>316.e2</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2009.03.023</pub-id><pub-id pub-id-type="pmid">19427992</pub-id></element-citation></ref><ref id="B76-medicina-60-00465"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Giuffrè</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Marchese</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Fogliato</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Miserocchi</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Modorati</surname><given-names>G.M.</given-names></name>
<name name-style="western"><surname>Sacconi</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Cicinelli</surname><given-names>M.V.</given-names></name>
<name name-style="western"><surname>Miere</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Amoroso</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Capuano</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>The “Sponge sign”: A novel feature of inflammatory choroidal neovascularization</article-title><source>Eur. J. Ophthalmol.</source><year>2021</year><volume>31</volume><fpage>1240</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1177/1120672120917621</pub-id><pub-id pub-id-type="pmid">32345048</pub-id></element-citation></ref><ref id="B77-medicina-60-00465"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Invernizzi</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Pichi</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Symes</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Zagora</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Agarwal</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Erba</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Xhepa</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>De Simone</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Cimino</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti vascular endothelial growth factors: A comparison between two treatment regimens</article-title><source>Br. J. Ophthalmol.</source><year>2020</year><volume>104</volume><fpage>1052</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2019-315257</pub-id><pub-id pub-id-type="pmid">31744798</pub-id></element-citation></ref><ref id="B78-medicina-60-00465"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wu</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zuo</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wen</surname><given-names>F.</given-names></name>
</person-group><article-title>Clinical characteristics of inflammatory choroidal neovascularization in a Chinese population</article-title><source>Ocul. Immunol. Inflamm.</source><year>2016</year><volume>24</volume><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.3109/09273948.2015.1015741</pub-id><pub-id pub-id-type="pmid">26171640</pub-id></element-citation></ref><ref id="B79-medicina-60-00465"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Weng</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Mao</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Spectral-domain optical coherence tomography angiography findings in multifocal choroiditis with active lesions</article-title><source>Am. J. Ophthalmol.</source><year>2016</year><volume>169</volume><fpage>145</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2016.06.029</pub-id><pub-id pub-id-type="pmid">27349415</pub-id></element-citation></ref><ref id="B80-medicina-60-00465"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zahid</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>K.C.</given-names></name>
<name name-style="western"><surname>Jung</surname><given-names>J.J.</given-names></name>
<name name-style="western"><surname>Balaratnasingam</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Ghadiali</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Sorenson</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Rofagha</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Freund</surname><given-names>K.B.</given-names></name>
<name name-style="western"><surname>Yannuzzi</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Optical coherence tomography angiography of chorioretinal lesions due to idiopathic multifocal choroiditis</article-title><source>Retina</source><year>2017</year><volume>37</volume><fpage>1451</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1097/IAE.0000000000001381</pub-id><pub-id pub-id-type="pmid">27880741</pub-id></element-citation></ref><ref id="B81-medicina-60-00465"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yee</surname><given-names>H.Y.</given-names></name>
<name name-style="western"><surname>Keane</surname><given-names>P.A.</given-names></name>
<name name-style="western"><surname>Ho</surname><given-names>S.L.</given-names></name>
<name name-style="western"><surname>Agrawal</surname><given-names>R.</given-names></name>
</person-group><article-title>Optical coherence tomography angiography of choroidal neovascularization associated with tuberculous serpiginous-like choroiditis</article-title><source>Ocul. Immunol. Inflamm.</source><year>2016</year><volume>24</volume><fpage>699</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.3109/09273948.2015.1109669</pub-id><pub-id pub-id-type="pmid">26829564</pub-id></element-citation></ref><ref id="B82-medicina-60-00465"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Aggarwal</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Agarwal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name>
</person-group><article-title>OCTA Study Group. Detection Of Type 1 Choroidal Neovascular Membranes Using Optical Coherence Tomography Angiography In Tubercular Posterior Uveitis</article-title><source>Retina</source><year>2019</year><volume>39</volume><fpage>1595</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1097/IAE.0000000000002176</pub-id><pub-id pub-id-type="pmid">29689028</pub-id></element-citation></ref><ref id="B83-medicina-60-00465"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Astroz</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Miere</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Mrejen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sekfali</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Souied</surname><given-names>E.H.</given-names></name>
<name name-style="western"><surname>Jung</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Nghiem-Buffet</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Cohen</surname><given-names>S.Y.</given-names></name>
</person-group><article-title>Optical coherence tomography angiography to distinguish choroidal neovascularization from macular inflammatory lesionns in multifocal choroiditis</article-title><source>Retina</source><year>2018</year><volume>38</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1097/IAE.0000000000001617</pub-id><pub-id pub-id-type="pmid">28368976</pub-id></element-citation></ref><ref id="B84-medicina-60-00465"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Theelen</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Berendschot</surname><given-names>T.T.J.M.</given-names></name>
<name name-style="western"><surname>Hoyng</surname><given-names>C.B.</given-names></name>
<name name-style="western"><surname>Boon</surname><given-names>C.J.F.</given-names></name>
<name name-style="western"><surname>Klevering</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Near-infrared reflectance imaging of neovascular age-related macular degeneration</article-title><source>Graefes Arch. Clin. Exp. Ophthalmol.</source><year>2009</year><volume>247</volume><fpage>1625</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.1007/s00417-009-1148-9</pub-id><pub-id pub-id-type="pmid">19641931</pub-id><pub-id pub-id-type="pmcid">PMC2776157</pub-id></element-citation></ref><ref id="B85-medicina-60-00465"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Toju</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Iida</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Sekiryu</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Saito</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Maruko</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Kano</surname><given-names>M.</given-names></name>
</person-group><article-title>Near-infrared autofluorescence in patients with idiopathic submacular choroidal neovascularization</article-title><source>Am. J. Ophthalmol.</source><year>2012</year><volume>153</volume><fpage>314</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2011.06.026</pub-id><pub-id pub-id-type="pmid">21982958</pub-id></element-citation></ref><ref id="B86-medicina-60-00465"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Samy</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Lightman</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ismetova</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Talat</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Tomkins-Netzer</surname><given-names>O.</given-names></name>
</person-group><article-title>Role of autofluorescence in inflammatory/infective diseases of the retina and choroid</article-title><source>J. Ophthalmol.</source><year>2014</year><volume>2014</volume><fpage>418193</fpage><pub-id pub-id-type="doi">10.1155/2014/418193</pub-id><pub-id pub-id-type="pmid">24800061</pub-id><pub-id pub-id-type="pmcid">PMC3995316</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="medicina-60-00465-f001" orientation="portrait"><label>Figure 1</label><caption><p>(<bold>a</bold>) Fundus autofluorescence image, showing hypoautofluorescence of inactive postinflammatory lesions (red arrows) and hyperautofluorescence of active inflammatory lesions (green asterix); irregular autofluorescence is present above the postinflammatory scar suspected for inflammatory choroidal neovascularization (yellow arrow); (<bold>b</bold>,<bold>c</bold>) fluorescein angiography images, showing early isofluorescence with late staining (<bold>d</bold>) of the lesions as a result of a retinal pigmented epithelium window defect; no evident features of inflammatory choroidal neovascularization are observed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g001.jpg"><?image-name medicina-60-00465-g001.jpg?><?image-size 57512?><?image-md5 3c2a02edf32b9d46fb1e7a208599e1ca?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1102?><?image-original-width 4277?><?image-scaled-height 200?><?image-scaled-width 777?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/3c2a02edf32b/medicina-60-00465-g001.jpg?><?thumb-name medicina-60-00465-g001.gif?><?thumb-size 11170?><?thumb-md5 8cd5ec6a0ee568f75cdae8fb78a40465?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 52?><?thumb-scaled-width 200?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/8cd5ec6a0ee5/medicina-60-00465-g001.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f002" orientation="portrait"><label>Figure 2</label><caption><p>(<bold>a</bold>) Color picture of the fundus showing inactive inflammatory foci in the macula region with changes at the retinal pigmented epithelium level; (<bold>b</bold>,<bold>c</bold>) fluorescein angiography images demonstrate early isofluorescence with late staining (<bold>d</bold>) of the lesions as a result of a retinal pigmented epithelium window defect without features of inflammatory choroidal neovascularization (red arrows).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g002.jpg"><?image-name medicina-60-00465-g002.jpg?><?image-size 64435?><?image-md5 ca18e2b5a462cd5d65e9e25cc39824fb?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1192?><?image-original-width 4325?><?image-scaled-height 217?><?image-scaled-width 786?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/ca18e2b5a462/medicina-60-00465-g002.jpg?><?thumb-name medicina-60-00465-g002.gif?><?thumb-size 9932?><?thumb-md5 b4bfc65235c35f71593e6612282503e7?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 55?><?thumb-scaled-width 200?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/b4bfc65235c3/medicina-60-00465-g002.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f003" orientation="portrait"><label>Figure 3</label><caption><p>(<bold>a</bold>) Fundus autofluorescence image shows hypoautoflurescence of inactive postinflammatory lesion in macula (red arrow) with hyperautofluorescent area representing the active inflammatory focus at its lower margin (green arrow), at the upper border of the scar the area of irregular autofluorescence is present (yellow arrow); (<bold>b</bold>,<bold>c</bold>) early and middle frames of indocyanine green (ICG) angiograms reveal a visibility of the choroidal vessels in the area of the inactive postinflammatory focus and small hypocyanescent area at its lower border corresponding to active choroidal inflammation; (<bold>d</bold>) late ICG angiogram demonstrates homogeneous hypocyanescence of the postinflammatory lesion with evidence of late hypercyanescence at its upper margin (yellow circle). The patient was diagnosed with inflammatory choridal neovascularization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g003.jpg"><?image-name medicina-60-00465-g003.jpg?><?image-size 54400?><?image-md5 8f351eda8f7fd4f5ddc2f54e1b176413?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1227?><?image-original-width 4434?><?image-scaled-height 205?><?image-scaled-width 739?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/8f351eda8f7f/medicina-60-00465-g003.jpg?><?thumb-name medicina-60-00465-g003.gif?><?thumb-size 9940?><?thumb-md5 afaf1a6103037b22a44096b02f8b14dc?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 55?><?thumb-scaled-width 200?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/afaf1a610303/medicina-60-00465-g003.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f004" orientation="portrait"><label>Figure 4</label><caption><p>(<bold>a</bold>,<bold>e</bold>) Color pictures of the fundus presenting well-defined and partially pigmented chorioretinal scars at the sites of previous chorioretinal inflammation in the macula of both eyes; (<bold>b</bold>,<bold>f</bold>) fundus autofluorescence demonstrate hypoautofluorescent foci that correlate with photoreceptor and retinal pigment epithelium damage; (<bold>c</bold>,<bold>d</bold>,<bold>g</bold>,<bold>h</bold>) early and late frames of indocyanine green angiograms revealed the presence of homogenous hypocyanescent foci related to retinal pigment epithelium damage due to postinflammatory scarring; no features of inflammatory choroidal neovascularization are observed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g004.jpg"><?image-name medicina-60-00465-g004.jpg?><?image-size 117168?><?image-md5 4b0745b26b8d538bd11c08821fd107e2?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1805?><?image-original-width 3540?><?image-scaled-height 401?><?image-scaled-width 786?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/4b0745b26b8d/medicina-60-00465-g004.jpg?><?thumb-name medicina-60-00465-g004.gif?><?thumb-size 11956?><?thumb-md5 1c16a8489d30287267a0ed46319b8116?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 80?><?thumb-scaled-width 156?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/1c16a8489d30/medicina-60-00465-g004.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f005" orientation="portrait"><label>Figure 5</label><caption><p>(<bold>a</bold>) Color picture of the right eye diagnosed for punctate inner choroidopathy; (<bold>b</bold>) optical coherence tomography scan demonstrates hyperreflective material above the retinal pigment epithelium with the presence of subretinal and intraretinal fluid corresponding to an active inflammatory choroidal neovascularization with multiple vertical finger-like projections extending anteriorly into the outer retina—the “pitchfork sign” (yellow arrows).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g005.jpg"><?image-name medicina-60-00465-g005.jpg?><?image-size 62899?><?image-md5 11710119007d5b4ac0b0bb17e09dd5d8?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1331?><?image-original-width 3321?><?image-scaled-height 296?><?image-scaled-width 738?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/11710119007d/medicina-60-00465-g005.jpg?><?thumb-name medicina-60-00465-g005.gif?><?thumb-size 12316?><?thumb-md5 e3546b16d30fb5d2fce7c15203479e5c?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 80?><?thumb-scaled-width 199?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/e3546b16d30f/medicina-60-00465-g005.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f006" orientation="portrait"><label>Figure 6</label><caption><p>(<bold>a</bold>) Color picture of the fundus shows macular subretinal fibrosis; (<bold>b</bold>) optical coherence tomography scan revealed hyperreflective material under the retinal pigment epithelium (yellow arrow), subretinal fluid is present (red arrow); (<bold>c</bold>–<bold>f</bold>) optical coherence tomography angiography (OCTA): the scan of the superficial capillary plexus is undisrupted (<bold>c</bold>); the scan of the deep capillary plexus shows a capillary impairment (<bold>d</bold>); the scans of outer retinal layer and choriocapillaris demonstrate pathological vessels presenting inflammatory choroidal neovascularization (iCNV) (yellow circles); (<bold>g</bold>) OCTA scan B presents the blood-flow in outer retinal layer (black arrows); (<bold>h</bold>) OCTA vessel density map is complementary and shows the presence of pathological vessels corresponding to iCNV (yellow circle).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g006.jpg"><?image-name medicina-60-00465-g006.jpg?><?image-size 172943?><?image-md5 bd2375c26861906ec0c8d2795781883a?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 2032?><?image-original-width 2667?><?image-scaled-height 581?><?image-scaled-width 762?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/bd2375c26861/medicina-60-00465-g006.jpg?><?thumb-name medicina-60-00465-g006.gif?><?thumb-size 10188?><?thumb-md5 83fae702c7cb35fabe784dbff0bcffcf?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 80?><?thumb-scaled-width 105?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/83fae702c7cb/medicina-60-00465-g006.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f007" orientation="portrait"><label>Figure 7</label><caption><p>(<bold>a</bold>,<bold>c</bold>) Color pictures of the right eye diagnosed for punctate inner choroidopathy; (<bold>b</bold>,<bold>d</bold>) optical coherence tomography scans demonstrate choroidal thickness (CT) changes under inflammatory choroidal neovascularization before and after the treatment—the “sponge sign”. Before treatment, CT corresponded to 257 µm and then decreased to 202 µm after intravitreal bevacizumab injection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g007.jpg"><?image-name medicina-60-00465-g007.jpg?><?image-size 81445?><?image-md5 f431c153bc464c4c9a81a99bd34dd66d?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1864?><?image-original-width 3321?><?image-scaled-height 414?><?image-scaled-width 738?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/f431c153bc46/medicina-60-00465-g007.jpg?><?thumb-name medicina-60-00465-g007.gif?><?thumb-size 9884?><?thumb-md5 a9687897846a1d6f90fa273b3b3641f8?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 80?><?thumb-scaled-width 142?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/a9687897846a/medicina-60-00465-g007.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f008" orientation="portrait"><label>Figure 8</label><caption><p>(<bold>a<sub>1</sub></bold>,<bold>a<sub>2</sub></bold>) Early and middle stages of indocyanine green angiography present hypocyanescent spots indicating active inflammatory lesions (red arrows); (<bold>a<sub>3</sub></bold>) late stage shows hypercyanescent plaque (green circle); (<bold>b</bold>–<bold>e</bold>) optical coherence tomography angiography (OCTA): the scan of the superficial apillary plexus is undisrupted (<bold>b</bold>); the scan of the deep capillary plexus shows a small area of capillary impairment below the macula (<bold>c</bold>); the scans of the outer retinal layer and choriocapillaris demonstrated pathological vessels presenting inflammatory choroidal neovascularization (green circles) (<bold>d</bold>,<bold>e</bold>); (<bold>f</bold>) OCTA B scan shows the presence of a trace of subretinal fluid (yellow arrow), blood flow in the outer retinal layers (green arrow), and intraretinal fluid (pink arrow), indicating the presence of active inflammatory choroidal neovascularization; (<bold>g</bold>) OCTA vessel density map presents a net of pathological vessels (yellow circle).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g008.jpg"><?image-name medicina-60-00465-g008.jpg?><?image-size 218022?><?image-md5 d482ef08550aa36fdc39e442566c924b?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 2154?><?image-original-width 2667?><?image-scaled-height 615?><?image-scaled-width 762?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/d482ef08550a/medicina-60-00465-g008.jpg?><?thumb-name medicina-60-00465-g008.gif?><?thumb-size 10665?><?thumb-md5 d93cb26c0132930f0c26c4fe6a546f27?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 81?><?thumb-scaled-width 100?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/d93cb26c0132/medicina-60-00465-g008.gif?></graphic></fig><fig position="float" id="medicina-60-00465-f009" orientation="portrait"><label>Figure 9</label><caption><p>(<bold>a</bold>) Early frame of fluorescein angiography demonstrates the presence of isofluorescence of the inactive inflammatory lesion related to serpiginous choroidopathy; (<bold>b</bold>) Late frame of fluorescein angiography presents hyperfluorescent area of inactive postinflammatory lesion as a result of a “window defect” with irregular staining above it (yellow arrow); (<bold>c</bold>–<bold>f</bold>) Optical coherence tomography angiography demonstrated normal superficial and deep capillary plexi (<bold>c</bold>,<bold>d</bold>); the scans of outer retina and choriocapillary layers show the net of pathological vessels (<bold>e</bold>,<bold>f</bold>); (<bold>g</bold>) OCTA B scan shows the presence of subretinal mass with blood flow (black arrows); (<bold>h</bold>) OCTA vessel density map presents a net of pathological vessels (yellow circle); (<bold>i</bold>) Optical coherence tomography presents the hyperreflective subretinal lesion (yellow arrow) with subretinal fluid (red arow) and intraretinal fluid (blue arrow) showing the evidence of active inflammatory choroidal neovasularization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00465-g009.jpg"><?image-name medicina-60-00465-g009.jpg?><?image-size 128482?><?image-md5 21d31854e915015845a77251271a54bb?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1951?><?image-original-width 3304?><?image-scaled-height 433?><?image-scaled-width 734?><?image-cloudpmc-urn urn:cdn:blobs/208f/10972505/21d31854e915/medicina-60-00465-g009.jpg?><?thumb-name medicina-60-00465-g009.gif?><?thumb-size 11696?><?thumb-md5 2423bee2bf1a052b82044365ca858074?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 80?><?thumb-scaled-width 135?><?thumb-cloudpmc-urn urn:cdn:blobs/208f/10972505/2423bee2bf1a/medicina-60-00465-g009.gif?></graphic></fig><table-wrap position="float" id="medicina-60-00465-t001" orientation="portrait"><object-id pub-id-type="pii">medicina-60-00465-t001_Table 1</object-id><label>Table 1</label><caption><p>Prevalence of inflammatory choroidal neovascularization (iCNV) depending on the etiology of uveitis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Uveitis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prevalence of iCNV [References] </th></tr></thead><tbody><tr><td colspan="2" align="center" valign="middle" rowspan="1">
<bold>Non-infectious</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multifocal choroiditis</td><td align="center" valign="middle" rowspan="1" colspan="1">32–50% [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B5-medicina-60-00465" ref-type="bibr">5</xref>,<xref rid="B6-medicina-60-00465" ref-type="bibr">6</xref>,<xref rid="B7-medicina-60-00465" ref-type="bibr">7</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Punctate inner choroidopathy</td><td align="center" valign="middle" rowspan="1" colspan="1">17–40% [<xref rid="B1-medicina-60-00465" ref-type="bibr">1</xref>,<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B8-medicina-60-00465" ref-type="bibr">8</xref>,<xref rid="B9-medicina-60-00465" ref-type="bibr">9</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Serpiginous choroidopathy</td><td align="center" valign="middle" rowspan="1" colspan="1">10–25% [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B10-medicina-60-00465" ref-type="bibr">10</xref>,<xref rid="B11-medicina-60-00465" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vogt–Koyanagi–Harada disease</td><td align="center" valign="middle" rowspan="1" colspan="1">9–15% [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B7-medicina-60-00465" ref-type="bibr">7</xref>,<xref rid="B9-medicina-60-00465" ref-type="bibr">9</xref>,<xref rid="B12-medicina-60-00465" ref-type="bibr">12</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Birdshot chorioretinitis</td><td align="center" valign="middle" rowspan="1" colspan="1">5% [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B13-medicina-60-00465" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intermediate uveitis</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B14-medicina-60-00465" ref-type="bibr">14</xref>,<xref rid="B15-medicina-60-00465" ref-type="bibr">15</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Behçet disease</td><td align="center" valign="middle" rowspan="1" colspan="1">very rare [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B16-medicina-60-00465" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acute posterior multifocal placoid pigment epitheliopathy</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B16-medicina-60-00465" ref-type="bibr">16</xref>,<xref rid="B17-medicina-60-00465" ref-type="bibr">17</xref>,<xref rid="B18-medicina-60-00465" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sympathetic ophthalmia</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B16-medicina-60-00465" ref-type="bibr">16</xref>,<xref rid="B19-medicina-60-00465" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sarcoidosis</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B9-medicina-60-00465" ref-type="bibr">9</xref>,<xref rid="B16-medicina-60-00465" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multiple evanescent white dot syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B20-medicina-60-00465" ref-type="bibr">20</xref>,<xref rid="B21-medicina-60-00465" ref-type="bibr">21</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" rowspan="1">
<bold>Infectious</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Histoplasmosis</td><td align="center" valign="middle" rowspan="1" colspan="1">5–17.4% [<xref rid="B4-medicina-60-00465" ref-type="bibr">4</xref>,<xref rid="B9-medicina-60-00465" ref-type="bibr">9</xref>,<xref rid="B16-medicina-60-00465" ref-type="bibr">16</xref>,<xref rid="B22-medicina-60-00465" ref-type="bibr">22</xref>,<xref rid="B23-medicina-60-00465" ref-type="bibr">23</xref>,<xref rid="B24-medicina-60-00465" ref-type="bibr">24</xref>,<xref rid="B25-medicina-60-00465" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Candidiasis</td><td align="center" valign="middle" rowspan="1" colspan="1">rare; prevalence unknown [<xref rid="B26-medicina-60-00465" ref-type="bibr">26</xref>,<xref rid="B27-medicina-60-00465" ref-type="bibr">27</xref>,<xref rid="B28-medicina-60-00465" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Toxoplasmosis</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3–19% [<xref rid="B29-medicina-60-00465" ref-type="bibr">29</xref>,<xref rid="B30-medicina-60-00465" ref-type="bibr">30</xref>,<xref rid="B31-medicina-60-00465" ref-type="bibr">31</xref>,<xref rid="B32-medicina-60-00465" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Toxocariasis</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B33-medicina-60-00465" ref-type="bibr">33</xref>,<xref rid="B34-medicina-60-00465" ref-type="bibr">34</xref>,<xref rid="B35-medicina-60-00465" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tuberculosis</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B36-medicina-60-00465" ref-type="bibr">36</xref>,<xref rid="B37-medicina-60-00465" ref-type="bibr">37</xref>,<xref rid="B38-medicina-60-00465" ref-type="bibr">38</xref>,<xref rid="B39-medicina-60-00465" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rubella retinopathy</td><td align="center" valign="middle" rowspan="1" colspan="1">single cases reported [<xref rid="B40-medicina-60-00465" ref-type="bibr">40</xref>,<xref rid="B41-medicina-60-00465" ref-type="bibr">41</xref>,<xref rid="B42-medicina-60-00465" ref-type="bibr">42</xref>,<xref rid="B43-medicina-60-00465" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">West Nile virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">single cases reported [<xref rid="B44-medicina-60-00465" ref-type="bibr">44</xref>,<xref rid="B45-medicina-60-00465" ref-type="bibr">45</xref>,<xref rid="B46-medicina-60-00465" ref-type="bibr">46</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>